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Abstract 
Introduction:  
Large-vessel vasculitis (LVV) is a serious illness with potentially life-threatening 
consequences. 18F-FDG PET-CT has emerged as a valuable diagnostic tool in suspected 
LVV, combining the strengths of functional and structural imaging. This study aimed to 
compare the accuracy of FDG PET-CT and contrast-enhanced CT (CECT) in the evaluation 
of patients with LVV.  
Materials and Methods:  
A retrospective database review for LVV patients undergoing CECT and PET-CT between 
2011 to 2016 yielded demographics, scan interval and vasculitis type. Qualitative and 
quantitative PET-CT analyses included aorta:liver FDG uptake, bespoke FDG uptake 
distribution scores and vascular maximum standardized uptake values (SUVmax). 
Quantitative CECT data were assessed wall thickness and mural/lumen ratio. ROC curves 
were constructed to evaluate comparative diagnostic accuracy and a correlational analysis 
was conducted between SUVmax and wall-thickness. 
Results:  
36 adults (17 LVV, 19 controls) with a mean age (range) 63 (38 ± 89) years, of which 17 
(47%) were males were included. Time interval between CT and PET was mean (standard 
deviation (SD)) 1.9 (1.2) months. Both SUVmax and wall-thickness demonstrated a 
significant difference between LVV and controls, with a mean difference (95% confidence 
interval (CI)) for SUVmax 1.6 (1.1, 2.0) and wall thickness 1.25 (0.68, 1.83) mm, 
respectively. These two parameters were significantly correlated (P<.0001, R = 0.62). The 
area under the curve (AUC) (95% CI) for SUVmax was 0.95 (0.88-1.00), and for mural 
thickening was 0.83 (0.66-0.99). 
Conclusions:  
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FDG PET-CT demonstrated excellent accuracy whilst CECT mural thickening showed good 
accuracy in the diagnosis of LVV. Both parameters showed a highly significant correlation. 
In hospitals without access to FDG PET-CT or in patients unsuitable for PET-CT (e.g. 
uncontrolled diabetes) CECT offers a viable alternative for the assessment LVV.  
Keywords:  
large vessel vasculitis, accuracy, FDG PET-CT, contrast enhanced CT  
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Introduction 
Large-vessel vasculitis (LVV) is a serious illness with potentially life-threatening 
consequences including aortic dissection, vessel rupture, blindness and stroke, and diagnosis 
is often delayed due to non-specific constitutional symptoms. The disease spectrum includes 
giant cell arteritis (GCA) and Takayasu arteritis (TA). 2-deoxy-2-(18Fluorine) fluoro-D-
glucose positron emission tomography-computed tomography (FDG PET-CT) has emerged 
as a valuable diagnostic tool in patients with suspected  LVV, combining the strengths of 
functional and structural imaging[1].  
As a non-specific biomarker of glycolytic metabolism, FDG PET-CT allows earlier detection 
of LVV, compared to traditional structural imaging, contrast-enhanced CT (CECT) [1, 2, 3]. 
However, adoption of FDG PET-CT into routine clinical diagnosis of LVV is challenging 
due to limited scanner availability and higher cost. Moreover, CECT may have a putative role 
in those unsuitable for FDG PET-CT such as those with uncontrolled diabetes. A cost-
effective alternative such as CECT would be highly attractive were it to be shown to be 
sufficiently accurate. A study by Muto and coworkers from Japan directly compared the 
accuracy of FDG PET-CT and CECT in patients with LVV[4]. An uncontrolled study by de 
Boysson and coworkers showed a good concordance between both modalities[5].  
We aimed to compare the diagnostic accuracy of FDG PET-CT and CECT in the evaluation 
of a cohort of patients with suspected LVV. Our purpose was also to validate the use of 
CECT assessment of vessel mural thickening as a surrogate for metabolic activity in a 
European population.  
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Materials and methods 
Patients 
Consecutive adult patients presenting with suspected LVV from December 2011 to March 
2016 at a large teaching hospital were identified using an institutional database search. Our 
control group were patients who were investigated for suspected LVV and who had FDG 
PET-CT and CECT but eventually were deemed not to have vasculitis by expert clinicians 
using a combination of clinical evaluation, follow-up, biochemical markers, temporal artery 
biopsy and imaging studies. Of these patients, only those who underwent both FDG PET-CT 
and CECT as part of their diagnostic pathway were included. All patients had a minimum of 
12-months clinical follow-up. Demographics, interval between CECT and PET-CT, 
treatment, and type of vasculitis were collated from electronic patient records. The 
Institutional Review Board issued a waiver for ethics approval and written informed consent 
for this retrospective anonymous data evaluation.  
The final clinical diagnosis of large vessel vasculitis was made by expert rheumatologists 
based on a combination of clinical findings, biochemical markers, imaging results, exclusion 
of other plausible diagnoses e.g. paraneoplastic syndromes, and response to standard 
treatment. 
 
PET-CT 
PET-CT scans were performed on a 64-slice Discovery 690 PET-CT scanner (GE Healthcare, 
Chalfont St Giles, UK). Serum blood glucose was routinely checked and if > 10 mmol/L, 
imaging was not performed. Patients fasted for at least 6 hours prior to intravenous injection 
of 18F-FDG (dose varied according to patient body weight). 60 minutes after tracer injection 
PET acquisition from skull vertex to upper thighs was performed. The low-dose, unenhanced 
CT component of the study was performed using a standardised protocol: 140 kV; 80 mAs; 
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tube rotation time 0.5s per rotation; pitch 6; section thickness 3.75 mm (to match the PET 
section thickness). Patients maintained normal shallow respiration during the CT acquisition. 
Images were reconstructed using a standard ordered subset expectation maximization 
(OSEM) algorithm with CT used for attenuation correction. Both non-attenuation corrected 
and attenuation corrected datasets were reconstructed. 
All PET-CT studies were re-installed from the institutional PACS archive and analysed using 
specialised software (Advantage Windows Version 4.5, GE Healthcare, Chalfont St Giles, 
UK). Qualitative and quantitative analyses of PET-CT data were performed including 
aorta:liver FDG uptake ratio, bespoke FDG uptake distribution scores and vascular maximum 
SUV (SUVmax). Firstly, an uptake score was created based on a technique used by Muto and 
coworkers [4]. Essentially, the vascular tree was divided into seven regions and each region 
was assigned an ordinal score based on the degree of activity as follows: 0 = no uptake, 1 = 
minimal but non-negligible FDG uptake, 2 = clearly increased FDG uptake, and 3 = marked 
FDG uptake. A total vascular score ranging from 0 (no vascular FDG uptake in seven 
vascular regions) to 21 (vascular FDG uptake = 3 in all seven regions), was calculated for 
each patient. Secondly, a bespoke PET score was modified from a study conducted by 
Papathanasiou and colleagues from University College of London (modified UCL score) [6]. 
The score ranged from: 0 = no uptake, 1 = minimal but not negligible uptake, 2 = uptake 
more than blood-pool but less than liver uptake, and 3 = uptake higher than liver activity. 
Thirdly, an aorta:liver SUVmax ratio was estimated[7]. Analysis of the PET data was 
performed by a dual-trained radionuclide radiologist with 5 years of experience in 
interpreting FDG PET-CT.  
 
CECT 
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Multi-detector CT scans was acquired as per standard protocol on a Siemens Somatom 64 
slice scanner (Siemens Healthcare GMBH, Munich , Germany), pitch 1.4, 120kV, 30 s post-
administration of 100 ml of iodinated contrast Niopam 300 (Bracco UK Ltd) and 
reconstructed with a 2 mm slice thickness. For the analysis we used a modified approach 
derived from the technique of Muto and co-workers to estimate aortic wall-thickness and 
mural-lumen ratio[4]. At least three cross-section levels of the descending thoracic aorta were 
chosen. At each cross-section, three measurements of the aortic wall thickness were taken (at 
R¶FORFNR¶FORFNDQGR¶FORFNSRVLWLRQVIURPZKLFKDQDYHUDJHZDVWKHQFDOFXODWHG
At the same position, a horizontal and vertical diameter was taken, and these were averaged 
too. This process was repeated at least 3 times down the length of the descending thoracic 
aorta, and an average was taken. The CECT analysis was performed by a radiologist with 3 
\HDUV¶H[SHULHQFH in CT and checked by a dual-trained consultant radionuclide radiologist 
and any disagreements were resolved through consensus.   
 
Statistical analysis 
Descriptive statistics were used for data from all patients. Continuous variables were 
analysed between JURXSVXVLQJ6WXGHQW¶VW-tests. Outcomes were assessed for normality using 
the Shapiro-Wilk test and by visual inspection of histograms and Q-Q plots, with 
consideration of previous datasets and literature. All patients were included in the analysis, 
which were performed on an intention-to-treat basis. We used scatter plots for the visual 
examination of between-group variables and to assess spread. Receiver operating 
characteristic curves were used to identify appropriate cut-offs between vasculitic and normal 
patients, and estimate overall test accuracy using the area under the receiver operating 
characteristic (ROC) curve (AUC). We chose to classify the diagnostic accuracy gleaned 
from the ROC analysis on a generally accepted classification system based on traditional 
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academic points: 0.90-1 = excellent; 0.80-0.90 = good; 0.70-0.80 = fair; 0.60-0.70 = poor; 
and 0.50-0.60 = fail. Statistical significance in all analyses was set at P < .05 (two-tailed). All 
statistical analyses were performed using SPSS version 17.0 (Chicago, Illinois, USA) and 
vector graphics were created on GraphPad Prism 5.0 for Macintosh (GraphPad Software Inc., 
San Diego, USA). 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
9 
Results 
Patient characteristics 
The study included 36 adults (17 LVV, 19 controls without LVV), of which 17 (47%) were 
male. The mean age (range) was 63 (38 ± 89) years. The two groups were comparable in 
terms of baseline characteristics and interval between imaging. The overall time interval 
between CT and PET-CT was mean (SD) 1.9 (1.2) months. The mean (SD) SUVmax was 3 
(1) and mural thickening was 2.37 (1.05) mm. Further details of overall and between-group 
patient demographics and baseline characteristics are detailed in Table 1.  
 
PET-CT scores 
All metabolic parameters including bespoke uptake scores were significantly different 
(P<.0001) between the LVV and control groups (Figure 1). The Muto and modified UCL 
scores demonstrated a significant difference between groups with mean differences (95% CI) 
as 12.0 (8.7 to 15.3) and 2.1 (1.7 to 2.5), respectively (P < .0001) (Figure 2). A Muto score 
cut-off of 3.5 resulted in a sensitivity and specificity of 79% and 94%, respectively. A UCL 
score cut-off of 1.5 resulted in a sensitivity and specificity of 89% each. The aorta-liver 
SUVmax ratio proved to be a highly specific measure, with only one patient from the control 
group with a ratio > 1. Using an aorta:liver SUVmax ratio > 1 as a cut-off resulted in a 
sensitivity of 76%, a specificity of  100%, a positive predictive value (PPV) of 100% and a 
negative predictive value (NPV) of 83% (Figure 3).  
 
CECT scores 
Mural thickening and mural-lumen ratios were significantly different between the LVV and 
control groups with a mean difference (95% CI): 1.26 (0.68 to 1.84) mm, and 0.04 (0.01 to 
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0.11) mm, respectively (Table 1, Figure 1). There was, however, a greater overlap of 
individual CECT derived scores compared to metabolic parameters. 
 
ROC curve analysis and correlation between PET-CT and CECT parameters 
The ROC curves demonstrated excellent accuracy for metabolic parameters and good 
accuracy for the morphological variables (Figure 4). The AUC (95% CI) for the modified 
UCL score was 0.93 (0.82 to 1.00) and for the Muto score was 0.96 (0.92 to 1.00). The AUC 
for mural thickening was 0.83 (0.66 to 0.99) and for mural-lumen ratio was 0.84 (0.69 to 
0.99). There was a significant correlation between SUVmax and wall-thickness with a high 
effect size (P <.0001; R =0.62) (Figure 5). 
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Discussion 
In this study, FDG uptake and wall-thickness demonstrated a highly significant correlation, 
and a high degree of accuracy in discriminating between LVV and controls. To the best of 
our knowledge, this is the first report validating the utility and comparability of 
morphological and metabolic surrogates of disease activity in LVV in a European population.  
 
All metabolic parameters including the bespoke vascular uptake scores were significantly 
different when comparing the LVV and control groups. These findings are in agreement with 
previous literature regarding the estimated sensitivity of FDG PET-CT in the diagnosis of 
LVV. FDG PET has a reported sensitivity of 80 - 92% and specificity of 89 - 100% in 
patients with LVV, with higher accuracy in GCA than in TA[6,8,9]. Existing American 
College of Rheumatology 1990 classification criteria for GCA, a composite of clinical, 
serological and histopathological items, are not suitable for diagnosis of GCA in clinical 
practice [10,11]. The benefits of FDG PET-CT over these diagnostic criteria include a higher 
sensitivity and accuracy, and the non-invasive nature of the test. Indeed, recent international 
guidelines for the non-oncological use of FDG PET-CT in inflammation list primary 
evaluation of vasculitides as a major indication[12]. Based on a meta-analysis of 12 studies 
(n=283), the guideline authors estimated the sensitivity and specificity of FDG PET-CT in 
LVV at 80% and 89%, respectively[12]. European League Against Rheumatism (EULAR) 
guidelines on LVV recommend FDG PET as an alternative to MRI for establishing the 
diagnosis but reiterate that lack of availability and formal validation is a limitation to the 
widespread endorsement in day-to-day practice[13]. In their absence, conventional 
angiography was recommended but this is unlikely to pick up early disease. A recent joint 
guideline by the European Association of Nuclear Medicine and the Society for Nuclear 
Medicine and Molecular Imaging concluded that based on available data, FDG PET-CT and 
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CT angiography may have an important role in the diagnosis of LVV but that additional 
randomised studies are needed to support this[14]. This highlights once again the evolving 
nature of evidence in this field. 
 
Although the bespoke FDG uptake scores demonstrated a high accuracy in our study, they are 
cumbersome to calculate and not practicable in routine clinical practice. Moreover, despite 
the high overall accuracy, there was still an overlap between disease and control groups when 
it came to individual scores. Indeed, the aorta:liver SUVmax ratio proved to be the simplest 
and most robust metabolic parameter with a 100% specificity and 100% NPV, and a higher 
overall accuracy than the bespoke scores. In day-to-day clinical practice, simple parameters 
are easier to interpret, whereas high specificity is important for avoiding false-positives due 
to atherosclerosis related FDG activity, particularly in this age group. Our results concur with 
Hautzel and co-workers¶ who showed that using a cut-off of aorta:liver SUVmax >1.0 in 
GCA resulted in a sensitivity, specificity, and accuracy of 89%, 95% and 94%[6]. In their 
study, the estimated specificity using the aorta:liver ratio was higher when compared to a 
meta-analysis (n=283) performed by Besson and co-workers[ 7]. 
 
CECT parameters showed a good accuracy in estimating the presence of LVV. Wall-
thickness showed an area under the ROC curve of 0.83 (95% CI: 0.66-0.99).  Unsurprisingly, 
in comparison to FDG PET-CT, this was less accurate most likely due to the metabolic-
morphological diagnostic gap which is a well-recognised phenomenon in the literature. These 
findings agree with de Boysson and coworkers which show a lower but good accuracy for 
contrast enhanced CT in LVV[5].  Although ours was a controlled study with a final 
diagnosis of LVV, our study design also had a degree of incorporation bias: since the 
reference standard (clinical diagnosis) incorporated the PET-CT findings, any error in the 
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PET-CT would have biased the reference standard in the same direction. In other words the 
correlation between error in PET-CT and error in reference standard could have resulted in an 
overestimation of PET-CT accuracy and underestimation of CECT accuracy. CECT may be a 
valuable alternative in patients unsuitable for FDG PET-CT such as uncontrolled diabetes, or 
in centres without reliable access to PET-CT. Another potential application for CECT could 
be patients already on glucocorticoid treatment because this is known to adversely affect the 
accuracy of FDG PET-CT in detecting LVV. For example, a study of 61 patients 
demonstrated that the diagnostic accuracy of FDG PET-CT was only 65% in patients on 
active treatment versus 93% in those who were treatment-naive (P=0.006)[8]. Also, a study 
by Blockmans et al. failed to show an additional value of serial PET scans post-treatment (at 
3 and 6 months), with no further reduction in large-vessel FDG uptake after 3 months of 
therapy[13]. This is likely due to effects of glucocorticoid therapy on relevant cellular 
functions such as glucose uptake. In such a scenario, FDG PET would not be useful in 
titrating long-term therapy as LWZRXOGEHOHVVVHQVLWLYHWR³IODUHV´RILQIODPPDWLRQZLWKLQWKH
vascular wall occurring during ongoing glucocorticoid therapy. It may be postulated that 
CECT mural thickening may fill this gap, but there are no current studies to validate this 
hypothesis. Lastly, in our experience there is a relatively steep learning curve for FDG PET-
CT in terms of test reliability and validity in diagnosing LVV (personal opinion, no data 
available). 
 
In our study, morphological and metabolic parameters were significantly correlated (P < 
.0001). This adds weight to the suggestion that CECT morphological parameters could be 
informative surrogates for LVV detection where PET-CT, the more sensitive test, is 
unavailable.  
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There are limitations to our study including its retrospective nature and relatively small 
sample size. However, we tried to obviate the effect of selection bias by including a control 
group. A degree of incorporation bias may have overestimated PET-CT accuracy and 
underestimated CECT accuracy. In future, volumetric metabolic parameters may provide a 
more comprehensive estimate of disease burden at baseline. Assessment of treatment 
response on CECT and PET warrants further evaluation in a prospective study.  
 
Conclusions 
FDG PET-CT demonstrated excellent accuracy whilst CECT mural thickening showed good 
accuracy for the diagnosis of LVV. Both parameters showed a highly significant correlation. 
In medical centres without access to FDG PET-CT or in patients unsuitable for PET-CT (e.g. 
uncontrolled diabetes), CECT may offer a good diagnostic alternative in the assessment of 
suspected LVV. 
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Figure and Table Legends 
 
Figure 1:  
Scatter plots of standard metabolic and morphological parameters in vasculitic and normal 
patients. SUVmax and SUVmax/liver ratio demonstrating a significant mean difference 
between LVV and controls, and wall-thickness and ratio show significant differences. Each 
symbol represents one patient. The error bars denote arithmetic mean and 95% confidence 
intervals. 
Figure 2:  
Bespoke vascular FDG uptake scores in vasculitis and normal patients demonstrating  
significant differences. Each symbol represents once patient. The error bars denote arithmetic 
mean and 95% confidence intervals. 
Figure 3:  
Stacked bar graph demonstrating the proportion of vasculitis patients diagnosed/excluded by 
using a binary cut-off of the ratio of the SUVmax of aorta and background liver. The high 
negative predictive value and specificity of the test are apparent by the complete exclusion of 
disease patients in those with an aorta:liver SUVmax ratio <1 seen in the right-side bar. 
Figure 4:  
Receiver operating characteristics curves for metabolic and morphological parameters 
demonstrating excellent accuracy for the former and good accuracy for the latter. The top two 
panels represent SUVmax/liver ratio and a bespoke FDG vascular uptake score with area 
under the curve (AUC) of 0.97 each. The bottom two panels are derived from contrast 
enhanced CT and demonstrate an AUC of 0.83 for wall-thickness and 0.84 for the mural-
lumen ratio. Please refer to the methods section for the derivation of these variables. 
 
Figure 5:  
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A correlation is demonstrated between SUVmax and wall-thickness indicating a high degree 
of agreement between FDG PET and CECT parameters. 
Table 1: Demographic, PET-CT-derived and CT-derived parameters of vasculitis and non-
vasculitis patients 
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Table 1: Demographic, PET-CT-derived and CT-derived parameters of vasculitis and non-
vasculitis patients 
 
Variable 
All 
(N = 36) 
Vasculitis 
(N = 17) 
Non-
vasculitis 
(N = 19) 
P-value for 
difference* 
Age, years, mean (range) 63 (38 ± 89) 64 (38 ± 89) 63 (42 ± 85) .79 
Sex, male, number (%) 17 (47) 5 (29) 12 (71)  
CT to PET time, months, mean (SD) 1.9 (1.2) 2.1 (1.3) 1.7 (1.0) .42 
PET positive Hautzel, number (%) 15 (42) 14 (93) 1 (7) <.0001¤ 
Modified UCL score, mean (SD) 1.7 (1.2) 2.8 (0.4) 0.7 (0.7) <.0001¤ 
Muto score, mean (SD) 7.6 (7.7) 13.9 (6.7) 1.9 (2.0) <.0001¤ 
SUVmax, mean (SD) 3.0 (1.0) 3.9 (0.8) 2.3 (0.5) <.0001¤ 
SUVmax/MBP, mean (SD) 1.4 (0.5) 1.9 (0.5) 1.1 (0.1) <.0001¤ 
SUVmax/liver, mean (SD) 1.1 (0.4) 1.4 (0.4) 0.8 (0.1) <.0001¤ 
Wall thickness, mm, mean (SD) 2.37 (1.05) 3.03 (1.16) 1.77 (0.42) Á 
Aorta diameter, mm, mean (SD) 28.64 (4.44) 29.45 (5.37) 27.93 (3.39) .31 
Wall/Diameter ratio, mean (SD) 0.08 (0.05) 0.11 (0.07) 0.01 (0.00)  
3YDOXHVGHULYHGIURP6WXGHQW¶VW-test for scale variables and Chi-squared test for categorical variables. 
3 
Á3 
¤ P <.0001 
Abbreviations ±PET: positron emission tomography, CT: computed tomography, SD: standard deviation, UCL: 
University College London score, SUVmax: standardized uptake value maximum; PET positive Hautzel, 
aorta:liver SUVmax ratio > 1; MBP, mediastinal blood pool. Details of the PET-CT and CT scoring systems 
are explicated in the methods section. 
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